Sedighim Shaina, Khorfan Rhami, Shin Jordan, Khan Aaqil, Tang Yixuan Irene, Li Amy Y, Senthil Maheswari, O'Leary Michael P, Eng Oliver S
Department of Surgery, University of California Irvine, Orange, CA, USA.
Department of Surgery, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Ann Surg Oncol. 2025 Apr;32(4):2292-2299. doi: 10.1245/s10434-024-16577-y. Epub 2024 Nov 22.
Patients with metastatic colorectal cancer (mCRC) often require multidisciplinary interventions due to the diversity of symptoms. Palliative treatment offers benefits including improved quality of life, yet sociodemographic disparities influence its utilization. This study aims to characterize these disparities in palliative treatment use among mCRC patients.
Utilizing data from the National Cancer Database, we identified patients diagnosed with mCRC between 2016 and 2020. Patients were categorized by metastatic site: peritoneal, liver, lung, or bone/brain/lymph node. Palliative treatment rates were compared across metastatic sites as well as patient and hospital factors.
A total of 106,241 patients were identified as having mCRC, with 19,208 (18.08%) receiving palliative treatment; 24.0% of patients with multiple metastatic disease and 14.0% of those with solely peritoneal metastases (PM) utilized palliative treatment (p < 0.001). Furthermore, patients over 75 years of age had a significantly decreased likelihood of receiving palliative treatment compared with younger patients (p = 0.0002). Hispanic patients did not differ significantly from non-Hispanic White populations (p = 0.47). Those in the highest education quartile demonstrated a higher degree of palliative treatment use compared with the lowest education quartile (p = 0.0081).
Among patients with mCRC, those with multiple sites of metastatic disease tend to receive higher rates of palliative treatment compared with those with oligometastatic disease. Patients with PM had the lowest rate of receiving palliative treatment. Other determinates of utilizing palliative treatment include younger age groups and higher education. Further research is warranted to understand the patterns of disparities in palliative treatment use among mCRC patients.
转移性结直肠癌(mCRC)患者由于症状多样,常常需要多学科干预。姑息治疗具有提高生活质量等益处,但社会人口学差异会影响其应用。本研究旨在描述mCRC患者在姑息治疗使用方面的这些差异。
利用国家癌症数据库的数据,我们确定了2016年至2020年间被诊断为mCRC的患者。患者按转移部位分类:腹膜、肝脏、肺部或骨/脑/淋巴结。比较了不同转移部位以及患者和医院因素的姑息治疗率。
共确定106241例患者患有mCRC,其中19208例(18.08%)接受了姑息治疗;有多处转移疾病的患者中24.0%使用了姑息治疗,而仅患有腹膜转移(PM)的患者中这一比例为14.0%(p<0.001)。此外,与年轻患者相比,75岁以上患者接受姑息治疗的可能性显著降低(p=0.0002)。西班牙裔患者与非西班牙裔白人人群之间无显著差异(p=0.47)。教育程度处于最高四分位数的患者与最低四分位数的患者相比,姑息治疗使用率更高(p=0.0081)。
在mCRC患者中,与寡转移疾病患者相比,有多处转移部位的患者往往接受更高比例的姑息治疗。患有PM的患者接受姑息治疗的比例最低。使用姑息治疗的其他决定因素包括较年轻的年龄组和较高的教育程度。有必要进一步开展研究以了解mCRC患者在姑息治疗使用方面的差异模式。